His scientific interests lie mostly in Internal medicine, Gastroenterology, Ribavirin, Hepatitis C and Surgery. His study in Internal medicine is interdisciplinary in nature, drawing from both Alpha interferon, Immunology and Hepatitis C virus. His biological study spans a wide range of topics, including Liver biopsy, Viral hepatitis, Virology, Peginterferon alfa-2b and Placebo.
His work in Ribavirin is not limited to one particular discipline; it also encompasses Viral load. His Surgery research is multidisciplinary, incorporating elements of Pediatrics and Transjugular intrahepatic portosystemic shunt. His Interleukin 28B research is multidisciplinary, relying on both Boceprevir and Telaprevir.
His primary areas of study are Internal medicine, Gastroenterology, Ribavirin, Cirrhosis and Hepatitis C. The Internal medicine study combines topics in areas such as Chronic hepatitis, Surgery, Immunology and Hepatitis C virus. His study in Gastroenterology is interdisciplinary in nature, drawing from both Fibrosis, Interferon, Placebo and Liver biopsy.
His Ribavirin study combines topics from a wide range of disciplines, such as Adverse effect and Alpha interferon. His Cirrhosis research incorporates themes from Hepatocellular carcinoma and Nonalcoholic fatty liver disease. His Hepatitis C research incorporates elements of Viral hepatitis, Pharmacotherapy, Randomized controlled trial and Hepatology.
His primary scientific interests are in Internal medicine, Gastroenterology, Cirrhosis, Placebo and Fibrosis. His studies in Internal medicine integrate themes in fields like Sofosbuvir/velpatasvir, Ribavirin and Hepatitis C virus. His Ribavirin research focuses on subjects like Alpha interferon, which are linked to Peginterferon alfa-2a and Viral load.
His work deals with themes such as Adverse effect, Randomized controlled trial and Obeticholic acid, which intersect with Gastroenterology. His work investigates the relationship between Cirrhosis and topics such as Hepatocellular carcinoma that intersect with problems in Pediatrics and Liver transplantation. His studies deal with areas such as Nonalcoholic fatty liver disease, Biopsy, Liver biopsy and Steatosis as well as Fibrosis.
His scientific interests lie mostly in Internal medicine, Gastroenterology, Cirrhosis, Placebo and Fibrosis. His study looks at the relationship between Internal medicine and topics such as Hepatitis C virus, which overlap with Regimen. Mitchell L. Shiffman has researched Gastroenterology in several fields, including Surgery, Liver biopsy, Adverse effect and Nonalcoholic fatty liver disease, Fatty liver.
His biological study spans a wide range of topics, including Liver disease, Steatohepatitis and Hazard ratio, Confidence interval. His research integrates issues of Ursodeoxycholic acid, Tolerability, Clinical endpoint, Randomized controlled trial and Primary sclerosing cholangitis in his study of Placebo. Immunology covers Mitchell L. Shiffman research in Ribavirin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried;Mitchell L. Shiffman;K. Rajender Reddy;Coleman Smith.
The New England Journal of Medicine (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi.
The Lancet (2001)
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman.
The New England Journal of Medicine (1998)
Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities
Arun J. Sanyal;Carol Campbell-Sargent;Faridoddin Mirshahi;William B. Rizzo.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong.
The New England Journal of Medicine (2003)
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir.
The New England Journal of Medicine (2009)
Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
Gary L. Davis;Rafael Esteban-Mur;Vinod Rustgi;John Hoefs.
The New England Journal of Medicine (1998)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro.
The New England Journal of Medicine (2014)
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane.
The New England Journal of Medicine (2008)
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
Pouneh Mofrad;Melissa J. Contos;Mahmadul Haque;Carol Sargeant.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: